The Oncology Institute Reports Fourth Quarter and Full Year 2025 Financial Results and Guidance for 2026
Go back to The Oncology Institute Reports Fourth Quarter and Full Year 2025 Financial Results and Guidance for 2026| TARGETS Trust XXIV 7% TARGETS with respect to the common stock of Intel Corporation (NASDAQ: TOI) | Delayed: 5.39 +0.27 (5.27%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $5.12 | 52 Week High | $7.47 | |||
| Open | $5.15 | 52 Week Low | $7.47 | |||
| Day High | $5.42 | P/E | N/A | |||
| Day Low | $5.04 | EPS | $0.00 | |||
| Volume | 5,202,821 | |||||
| TARGETS Trust XXIV 7% TARGETS with respect to the common stock of Intel Corporation (NASDAQ: TOI) | Delayed: 5.39 +0.27 (5.27%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $5.12 | 52 Week High | $7.47 | |||
| Open | $5.15 | 52 Week Low | $7.47 | |||
| Day High | $5.42 | P/E | N/A | |||
| Day Low | $5.04 | EPS | $0.00 | |||
| Volume | 5,202,821 | |||||
